

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2008 (31.01.2008)

PCT

(10) International Publication Number
WO 2008/012629 A3

(51) International Patent Classification:

C07K 14/575 (2006.01) **C12N 15/63** (2006.01)
C07K 19/00 (2006.01) **C12N 15/62** (2006.01)
A61K 38/22 (2006.01)

(74) Agent: **FULLER, Grover, F., Jr.**; c/o McGraw George,
Nancy, Pfizer Inc. MS8260-1615, Eastern Point Road,
Groton, PA 06340 (US).

(21) International Application Number:

PCT/IB2007/002047

(22) International Filing Date: 13 July 2007 (13.07.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/832,582 24 July 2006 (24.07.2006) US
60/857,474 8 November 2006 (08.11.2006) US
60/874,965 15 December 2006 (15.12.2006) US

(71) Applicant (for all designated States except US):
BIOREXIS PHARMACEUTICAL CORPORATION [US/US]; 3400 Horizon Drive, King Of Prussia,
Pennsylvania 19406-2675 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SADEGHI, Homayoun** [US/US]; 3400 Horizon Drive, King of Prussia, Pennsylvania 19406 (US). **PRIOR, Christopher, Philip** [US/US]; 3400 Horizon Drive, King of Prussia, Pennsylvania 19406 (US). **BALLANCE, David, James** [GB/US]; 3400 Horizon Drive, King of Prussia, Pennsylvania 19406 (US). **TURNER, Andrew, John** [GB/US]; 3400 Horizon Drive, King of Prussia, Pennsylvania 19406 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:

8 May 2008

(54) Title: EXENDIN FUSION PROTEINS

(57) Abstract: The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.



WO 2008/012629 A3